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ABSTRACT
Objectives To determine the associations between 
comorbidities, health- related quality of life (HRQoL) and 
functional impairment in people with mild- to- moderate 
chronic kidney disease (CKD) in primary care.
Design Cross- sectional analysis at 5- year follow- up in a 
prospective cohort study.
Setting Thirty- two general practitioner surgeries in 
England.
Participants 1008 participants with CKD stage 3 (of 1741 
people recruited at baseline in the Renal Risk in Derby 
study) who survived to 5 years and had complete follow- up 
data for HRQoL and functional status (FS).
Primary and secondary outcome measures HRQoL 
assessed using the 5- level EQ- 5D version (EQ- 5D- 5L, 
with domains of mobility, self- care, usual activities, pain/
discomfort and anxiety/depression and index value 
using utility scores calculated from the English general 
population), and FS using the Karnofsky Performance 
Status scale (functional impairment defined as Karnofksy 
score ≤70). Comorbidity was defined by self- reported or 
doctor- diagnosed condition, disease- specific medication or 
blood result.
Results Mean age was 75.8 years. The numbers reporting 
some problems in EQ- 5D- 5L domains were: 582 (57.7%) 
for mobility, 166 (16.5%) for self- care, 466 (46.2%) for 
usual activities, 712 (70.6%) for pain/discomfort and 319 
(31.6%) for anxiety/depression. Only 191 (18.9%) reported 
no problems in any domain. HRQoL index values showed 
greater variation among those with lower FS (eg, for those 
with Karnofsky score of 60, the median (IQR) EQ- 5D index 
value was 0.45 (0.24 to 0.68) compared with 0.94 (0.86 
to 1) for those with Karnofsky score of 90). Overall, 234 
(23.2%) had functional impairment.
In multivariable logistic regression models, functional 
impairment was independently associated with 
experiencing problems for all EQ- 5D- 5L domains 
(mobility: OR 16.87 (95% CI 8.70 to 32.79, p<0.001, 
self- care: OR 13.08 (95% CI 8.46 to 20.22), p<0.001, 
usual activities: OR 8.27 (95% CI 5.43 to 12.58), 
p<0.001, pain/discomfort: OR 2.94 (95% CI 1.86 to 4.67), 
p<0.001, anxiety/depression: 3.08 (95% CI 2.23 to 4.27), 
p<0.001). Higher comorbidity count and obesity were 
independently associated with problems in mobility, self- 
care, usual activities and pain/discomfort: for three or 
more comorbidities versus none: (mobility: OR 2.10 (95% 
CI 1.08 to 4.10, p for trend 0.002), self- care: OR 2.64 
(95% CI 0.72 to 9.67, p for trend 0.05), usual activities: 
OR 4.20 (95% CI 2.02 to 8.74, p for trend <0.001), pain/
discomfort: OR 3.06 (95% CI 1.63 to 5.73, p for trend 
<0.001)), and for obese (body mass index (BMI) ≥30 kg/
m2) versus BMI <25 kg/m2: (mobility: OR 2.44 (95% CI 
1.61 to 3.69, p for trend <0.001), self- care: OR 1.98 
(95% CI 1.06 to 3.71, p for trend 0.003), usual activities: 
OR 1.82 (95% CI 1.19 to 2.76, p for trend 0.019), pain/
discomfort: OR 2.37 (95% CI 1.58 to 3.55, p for trend 
<0.001)). Female sex, lower FS and lower educational 
attainment were independently associated with anxiety/
depression (ORs 1.60 (95% CI 1.18 to 2.16, p 0.002), 3.08 
(95% CI 2.23 to 4.27, p<0.001) and 1.67 (95% CI 1.10 to 
2.52, p 0.009), respectively). Older age, higher comorbidity 
count, albuminuria (≥30 mg/mmol vs <3 mg/mmol), lower 
educational attainment (no formal qualifications vs degree 
level) and obesity were independently associated with 
functional impairment (ORs 1.07 (95% CI 1.04 to 1.09, 
p<0.001), 2.18 (95% CI 0.80 to 5.96, p for trend <0.001), 
Strengths and limitations of this study
 ► This study involved a large cohort of people with 
chronic kidney disease (CKD) recruited from pri-
mary care, a setting in which patients with mild- to- 
moderate CKD are typically managed in the UK.
 ► A broad range of comorbidities were included but 
they were identified at baseline only, not at follow- 
up, by which time the number of comorbidities may 
have changed.
 ► Health- related quality of life and functional status 
were measured in the same patient group and the 
use of the EQ- 5D- 5L index measure and data from 
the Health Survey for England enabled comparison 
with a general population.
 ► Health- related quality of life and functional status 
measures were taken at 5- year follow- up but not 
at baseline and we were therefore unable to identify 
change over time.
 ► This was a cross- sectional study of survivors and 
we are therefore not able to draw causative links.
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1.74 (95% CI 0.82 to 3.68, p for trend 0.005), 2.08 (95% CI 1.26 to 3.41, p 
for trend <0.001) and 4.23 (95% CI 2.48 to 7.20), respectively).
Conclusions The majority of persons with mild- to- moderate CKD 
reported reductions in at least one HRQoL domain, which were 
independently associated with comorbidities, obesity and functional 
impairment.
Trial registration number National Institute for Health Research Clinical 
Research Portfolio Study Number 6632.
INTRODUCTION
Chronic kidney disease (CKD) is common globally, 
affecting about 13% of the general adult population, 
with CKD stage 3 the most prevalent category.1 2 Current 
treatment guidelines for CKD are disease specific and 
focus on reducing progression and preventing complica-
tions such as cardiovascular disease.3 However, in the UK, 
most people with CKD stage 3 are managed in primary 
care and in this context only a minority (18%) evidence 
progression over 5 years.4 The risk of end- stage kidney 
disease (ESKD) is extremely low (0.2%).4
Conversely, comorbidities (additional chronic diseases) 
are common in individuals with CKD and can worsen clin-
ical outcomes and health- related quality of life (HRQoL).5 
Ninety- six per cent of people with stage 3 disease have at 
least one comorbidity, around 40% have a comorbidity 
count of two or more.6
A significant body of research has explored HRQoL 
and the functional status (FS) of people with ESKD or 
following kidney transplant but these factors are not 
well explored in those with less severe CKD. Among 733 
people with high- risk CKD in the Renal Impairment In 
Secondary Care study, 555 (76%) reported problems in 
one or more of the EQ5D domains.7 8
This is a clinically important knowledge gap because 
mild- to- moderate reductions in glomerular filtration rate 
(GFR) are usually asymptomatic, so improved under-
standing of the comorbidities and symptoms that affect 
HRQoL and FS in this group of people is important to 
facilitate a holistic approach to management. The objec-
tive of this study was therefore to evaluate HRQoL and 
determine the associations between comorbidities, 
HRQoL and functional impairment in people with mild- 
to- moderate CKD in primary care.
MATERIALS AND METHODS
A detailed description of the Renal Risk in Derby (RRID) 
study methodology has been published elsewhere.9 In 
summary, approximately 8280 people with CKD stage 3 
were identified from renal registers at 32 primary care 
clinics in Derbyshire, UK, between 2008 and 2010 and 
invited to participate in the study. Of these people, 1822 
attended initial baseline visits and 1741 met eligibility 
criteria (age ≥18 years; two estimated GFR (eGFR) results 
(derived from the Modification of Diet in Renal Disease 
study (MDRD) equation) of 30–59 mL/min/1.73 m2, at 
least 90 days apart).9 People with a life expectancy of less 
than 1 year, who were unable to attend study visits, or who 
had a solid organ transplant were excluded.
Health-related quality of life
HRQoL was assessed at 5- year follow- up using the 
EQ- 5D- 5L, a widely used, validated measure of health 
status that can be standardised to different populations. 
EQ- 5D- 5L consists of two aspects: a descriptive system, 
in which participants are asked to rate their health state 
from 1 to 5 against five domains (mobility, self- care, usual 
activities, pain/discomfort, anxiety/depression) and the 
EQ visual analogue scale (EQ- VAS), in which partici-
pants rate their health on a scale ranging from ‘the best 
health you can imagine’ (100) to ‘the worst health you 
can imagine’ (0).10 An EQ- 5D- 5L value set has previously 
been published for England.11 However, concerns have 
been raised about the quality and reliability of the data 
collected in the valuation study such that the English 
National Institute for Health and Care Excellence (NICE) 
recommend ‘If data were gathered using the EQ- 5D- 5L 
descriptive system, utility values in reference- case anal-
yses should be calculated by mapping the 5 L descriptive 
system data onto the 3 L value set’.12 For these analyses, 
individual health states were therefore converted using 
the EuroQol EQ- 5D- 5L Crosswalk Index Value Calculator 
into a single 3L index value (a preference- based score 
that typically ranges from states worse than dead (<0) to 1 
(full health) with dead at 0) using utility scores calculated 
from the English general population.13 14 The index value 
and the EQ- VAS score were used to graphically display the 
relationship between HRQoL and FS.
Functional status
FS, defined in this paper as the physical ability to perform 
normal activities and independently self- care, was 
assessed at 5- year follow- up using the Karnofsky Perfor-
mance Status (KPS) scale. The KPS is a clinician- assessed 
score originally developed in oncology and was used for 
assessing prognosis and management in patients with 
cancer.15 The scale ranges from ‘normal/no complaints’ 
(100) to ‘dead’ (0). Theoretically, the scale can take 
any whole number value within the range, but in prac-
tice results are commonly recorded as multiples of 10; 
therefore, KPS was treated as an ordinal variable in this 
study. The original continuous KPS score >70 is defined 
as being ‘able to carry on normal activity and to work 
with no special care needed’, a score of between 50 and 
70 inclusive is defined as ‘unable to work, able to live at 
home and care for most personal needs; varying amount 
of assistance needed’, and a score of less than or equal 
to 40 is defined as ‘unable to care for self, requiring the 
equivalent of institutional or hospital care’.15 Functional 
impairment was analysed as a binary outcome due to the 
small number of patients with low KPS score. A KPS score 
of ≤70 versus >70 was chosen to compare those able to 
carry on normal life with those experiencing some func-
tional impairment as has been used in evaluation of FS in 
patients with lung cancer.16
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Comorbidities identified at baseline
The methods for defining comorbidities in participants 
have been described in detail elsewhere.6 In brief, eleven 
comorbidities were pragmatically identified at baseline 
using information from a combination of sources and 
agreed by consensus between three clinicians (SF, MWT 
and PJR): patient questionnaires in which patients were 
asked to list chronic medications (followed by verbal 
confirmation with verification of repeat prescriptions 
where possible), blood pressure measurement at the time 
of baseline study visit and self- reported clinical diagnoses. 
Self- reported comorbidities included heart failure, isch-
aemic heart disease, peripheral vascular disease (defined 
as peripheral arterial revascularisation or amputation) 
and cerebrovascular disease (stroke or transient isch-
aemic attack). Diagnoses of chronic respiratory disorder, 
depression, painful condition, hypertension, diabetes and 
thyroid disorders were made according to medication 
history or patient report. Anaemia was defined according 
to Kidney Disease Improving Global Outcomes (KDIGO) 
guidelines as haemoglobin <13.0 g/dL (<130 g/L) in 
men and <12.0 g/dL (<120 g/L) in women, at baseline.17 
Hypertension was defined either by medication history, 
or by a systolic blood pressure >140 mm Hg or diastolic 
>90 mm Hg, at baseline.
Kidney function
Kidney function was assessed at 5- year follow- up. eGFR 
was calculated using the Chronic Kidney Disease Epide-
miology Collaboration equation and was treated as a 
continuous variable. The urine albumin- to- creatinine 
ratio (uACR) from three consecutive early morning spec-
imens was used for analysis. uACR was categorised into 
three levels according to KDIGO guidelines and fitted as 
a discrete variable in regression analyses.
Methods for defining CKD progression have also been 
detailed elsewhere.4 In summary, progression of CKD was 
defined as a 25% decline in GFR, coupled with a wors-
ening of GFR category or an increase in albuminuria 
category. CKD remission was defined as the presence of 
both eGFR >60 mL/min/1.73 m2 and uACR <3 mg/mmol 
at any study visit in an individual who had previously met 
KDIGO diagnostic criteria for CKD.
Other baseline measures
Body mass index (BMI) was calculated from weight in 
kilograms divided by square of height in metres and was 
treated as a categorical variable.18 Smoking status was 
categorised as never smoked, ex- smoker and current 
smoker. Socioeconomic status was assessed using self- 
reported educational attainment (categorised into no 
formal qualifications, school or equivalent qualifications, 
and degree or equivalent qualifications) as well as the 
Index of Multiple Deprivation (IMD) score, categorised 
in quintiles.19 The IMD is a measure of relative depriva-
tion for small areas of residence in England and combines 
information from seven domains: income; employment; 
education, skills and training; health and disability; crime; 
barriers to housing and services; and living environment. 
Self- reported ethnicity status was also collected.
Statistical analyses
Descriptive statistics were used to show the characteris-
tics of the study participants at 5- year follow- up. Descrip-
tive statistics were also used to show the distribution of 
functional impairment (KPS ≤70) among those reporting 
problems in the five EQ- 5D- 5L domains. Associations 
between the patient- reported EQ- 5D- 5L domains and 
FS was assessed using the χ2 test. Ratings from the five 
participant- reported EQ- 5D- 5L domains were also 
compared between the RRID cohort and those reported 
by people aged 65 years and over in the 2012 Health 
Survey for England (HSE)—which is representative of 
the England population.20 A comparison of basic charac-
teristics was also made between those with and without 
complete 5- year follow- up data.
Univariable logistic regression models were used to 
assess the relationships between having ‘some problems’ 
in each EQ- 5D- 5L domain and each predictor variable, 
including comorbidity count and year- five eGFR. Vari-
ables considered to be clinically relevant and where p<0.1 
on univariable analysis were subsequently included in 
multivariable logistic regression models. This process was 
then repeated for the relationship with the outcome vari-
able functional impairment. Due to the small number of 
non- white participants, ethnicity was not included in the 
models.
In the regression models, interactions between the 
individual and area measures of socioeconomic status 
were also tested because of the potential for the relation-
ship between individual socioeconomic status (indicated 
by educational attainment) and HRQoL to vary by area 
deprivation, particularly for older people.21 The level of 
significance was set at 5%. All analyses were performed 
using Stata/IC V.15.0.
Patient and public involvement
The RRID study design was discussed with a patient and 
two feedback meetings for participants and their fami-
lies were organised after the year 5 visits, which were well 
attended. In addition, a web page provides updates and 
information for participants (https://www. uhdb. nhs. uk/ 
renal- risk- in- derby- rrid- study/).
RESULTS
Of 1741 participants recruited, 1494 survived to 5 years, 
and of these 1008 participants (67% of survivors) had 
complete 5- year follow- up data for HRQoL and FS 
(figure 1). The mean age of the cohort was 75.8 years 
(SD 8.6) and the majority (n=621, 61.6%) were female 
(table 1).
Approximately half (n=506, 50.3%) reported having 
had no formal education, just under half (n=497, 49.4%) 
lived in areas of lower deprivation (IMD quintiles four or 
five) and the majority (n=994, 98.6%) were white. The 
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mean eGFR at follow- up was 54.0 mL/min/1.73 m2 (SD 
15.2) and almost half (n=460, 45.6%) had had stable 
CKD over the preceding 5- year period. Only 56 (5.6%) 
had no comorbidities and about a third (n=344, 34.1%) 
had three or more comorbidities. For comparison of 
basic characteristics of those with and without complete 
5- year follow- up data, see online supplementary table S1. 
A slightly higher proportion of those with incomplete 
follow- up data had three or more comorbidities and 
only a very small proportion had functional impairment 
(online supplementary table S1).
The majority reported some impairment in HRQoL 
overall, with a median score of 75 out of 100 (IQR 60–90) 
on the EQ- VAS. A minority (n=378, 37.5%) had an 
EQ- 5D- 3L index score higher than the age/sex matched 
median, and only 18.9% of people (n=191) reported no 
problems across any of the individual HRQoL domains. 
Furthermore, a majority of participants reported some 
problems with mobility (n=582, 57.7%) and pain/discom-
fort (n=712, 70.6%; table 1).
When comparing the self- reported HRQoL domains 
with HSE data, the proportion of people in the RRID 
population reporting problems with mobility or pain/
discomfort was higher (57.7% vs 50.4%, and 70.6% vs 
60.1%, respectively) than in the HSE population (table 2).
For clinician- assessed FS, only two participants had 
performance status assessed as KPS ≤40 (‘unable to 
care for self, requiring the equivalent of institutional or 
hospice care’) and 232 (23%) were assessed as KPS 50–70 
(‘unable to work; able to live at home and care for most 
personal needs; varying amount of assistance needed’).
The association between clinician- assessed FS and 
patient- reported HRQoL was complex, either when 
based on the index score (figure 2A) or the VAS scale 
(figure 2B). HRQoL was generally higher among those 
with better FS. However, the spread of HRQoL scores 
(using either of the HRQoL metrics) was broader among 
those with lower FS, suggesting a greater degree of varia-
tion in HRQoL among those with lower FS than among 
those with higher FS (figure 2). A higher proportion of 
people with clinician- assessed functional impairment 
(KPS ≤70) reported having some degree of problems in 
each of the five EQ- 5D- 5L domains than people without 
functional impairment (online supplementary table S2).
Using the mobility domain as an example (table 3), on 
univariable analysis older age, greater area deprivation 
level, higher number of comorbidities, poorer FS, lower 
eGFR, higher level of albuminuria, lower educational 
attainment and higher BMI were associated with having 
some problems.
In the fully adjusted multivariable model, these associ-
ations remained for older age, higher number of comor-
bidities, poorer FS and higher BMI (table 3). A summary 
of the main independent associations identified in the 
multivariable logistic regression models for usual activi-
ties, self- care, pain/discomfort and anxiety/depression is 
shown in table 4 and the full analyses in online supple-
mentary tables S3 to S6.
Figure 1 Flow chart of study participants. CKD, chronic kidney disease; KDIGO, Kidney Disease Improving Global Outcomes; 
GP, general practitioner; QoL, quality of life.
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Factors associated with a lower FS on univariable 
analysis included older age, lower socioeconomic status 
(assessed by both IMD score and educational attain-
ment), higher number of comorbidities, obesity, reduced 
eGFR and greater degree of albuminuria. Other than 
reduced eGFR, all of these factors remained significant 
after adjustment (table 5). No interactions were identi-
fied in any analyses.
DISCUSSION
In this cross- sectional study of people with mild- to- 
moderate CKD who survived to year 5 in a UK primary care 
cohort, overall patient- reported HRQoL was relatively high 
Table 1 Characteristics of patients at 5- year follow- up in 
the Renal Risk in Derby study, n=1008 unless otherwise 
stated
Variable Category
Descriptive 
statistics
Age in years,* 
mean (SD)
  75.8 (8.6)
Age group,* n (%) <70 years 220 (21.8)
70–80 years 467 (46.3)
>80 years 321 (31.8)
Sex,† n (%) Male 387 (38.4)
Female 621 (61.6)
Ethnicity,† n (%) White 994 (98.6)
Other‡ 14 (1.4)
Educational 
attainment,† n (%) 
(n=1007)
No formal qualifications 506 (50.3)
GCSE, A level, NVQ 1–3 291 (28.9)
First or higher degree, 
NVQ 4–5
210 (20.9)
Index of Multiple 
Deprivation (IMD 
quintile relative to 
England),† n (%) 
(n=1006)
Quintile 1 (most deprived) 82 (8.2)
Quintile 2 243 (24.2)
Quintile 3 184 (18.3)
Quintile 4 258 (25.6)
Quintile 5 (least deprived) 239 (23.8)
Body mass 
index,† n (%)
Normal or underweight 
(<25 kg/m2)
195 (19.3)
Overweight (25–29.99 kg/
m2)
422 (41.9)
Obese (≥30 kg/m2) 391 (38.8)
Smoking status,† 
n (%)
Never smoked 496 (49.2)
Ex- smoker 468 (46.4)
Current smoker 44 (4.4)
eGFR* in mL/min/1.73 m2, mean (SD) (n=1007) 54.0 (15.2)
uACR* in mg/mmol, median (IQR) (n=1007) 0.7 (0–3.3)
KDIGO uACR 
categories* n (%)
A1 741 (73.5)
A2 217 (21.5)
A3 50 (5.0)
KDIGO eGFR 
categories* (eGFR 
in mL/min/1.73 m2)
G1 (eGFR ≥90) 13 (1.3)
G2 (eGFR 60–89) 337 (33.4)
G3a (eGFR 45–59) 379 (37.6)
G3b (eGFR 30–44) 223 (22.1)
G4 (eGFR 15–29) 55 (5.5)
G5 (eGFR <15) 1 (0.1)
Progression of 
kidney disease,* 
n (%)
Stable 460 (45.6)
Progression 244 (24.2)
Remission 304 (30.2)
Number of 
comorbidities,† 
n (%)
None (CKD only) 56 (5.6)
One 308 (30.6)
Two 300 (29.8)
Three or more 344 (34.1)
Continued
Variable Category
Descriptive 
statistics
Individual 
comorbidities,† 
n (%)
Hypertension 874 (86.7)
Painful condition 300 (29.8)
Anaemia 201 (19.9)
Ischaemic heart disease 187 (18.6)
Diabetes 143 (14.2)
Thyroid disorder 127 (12.6)
Cerebrovascular disease 96 (9.5)
Chronic respiratory 
disorder
79 (7.8)
Depression 59 (5.9)
Peripheral vascular 
disease
29 (2.9)
Heart failure 24 (2.4)
Quality- of- life 
domains (any 
problems reported 
in each EQ- 5D- 5L 
domain, n (%))
Mobility problems 582 (57.7)
Self- care problems 166 (16.5)
Usual activity problems 466 (46.2)
Pain/discomfort 712 (70.6)
Anxiety/depression 319 (31.6)
No problems in any 
domain
191 (18.9)
Functional status* 
(KPS score), n (%)
Functional impairment 
(KPS ≤70)
234 (23.2)
KPS >70 (able to carry 
on normal activity and 
to work; no special care 
needed)
774 (76.8)
Where variable category percentages sum to less than or more 
that 100%, this is due to rounding.
*Variables assessed at year 5 follow- up.
†Variables assessed at baseline.
‡Includes mixed, Asian, Cypriot and other.
CKD, chronic kidney disease; eGFR, estimated glomerular filtration 
rate; GCSE, General Certificate of Secondary Education; KDIGO, 
Kidney Disease: Improving Global Outcomes; KPS, Karnofsky 
Performance Status; A level, advanced level; NVQ, National 
Vocational Qualifications; uACR, urine albumin- to- creatinine ratio.
Table 1 Continued
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though a substantial proportion of participants reported 
problems in each HRQoL domain. A majority reported 
problems with mobility and pain/discomfort. Although 
most people had a clinician- assessed FS suggesting that 
they were able to carry on normal activity and to work with 
no special care needed, about a quarter were assessed as 
having functional impairment (being unable to work but 
able to live at home and care for most personal needs 
with a varying amount of assistance needed). HRQoL was 
generally higher among those with better FS but there 
was more variation in HRQoL among those with lower 
FS, and low FS was independently strongly associated 
with low HRQoL in regression analyses. Higher number 
of comorbidities and obesity were independently associ-
ated with problems in most EQ- 5D- 5L domains and with 
functional impairment. Functional impairment was inde-
pendently associated with experiencing some problems 
across all EQ- 5D- 5L domains.
This study had several strengths, including the large 
size of the cohort, and recruitment from primary care, 
a setting in which patients with mild- to- moderate CKD 
are typically managed. The RRID cohort is pragmatic 
and likely to represent a population of typical patients 
with mild- to- moderate CKD in the UK.22 23 We were able 
to identify a broad range of comorbidities but they were 
identified at baseline only. The number of comorbidities 
may therefore have changed by the time of follow- up 
assessment, meaning that our comorbidity prevalence 
data were likely underestimates of the true prevalence 
in some patients. Similarly, certain other exposures were 
assessed at baseline and could potentially have changed 
by the time of follow- up. We recognise these as important 
limitations but consider that they are unlikely to signifi-
cantly alter the main findings of our study with regard to 
HRQoL and FS. A further strength is that we were able to 
measure HRQoL and FS in the same patient group and 
the HRQoL and FS data were relatively complete. The use 
of the EQ- 5D- 5L index measure and data from the HSE 
enabled comparison with a general population. However, 
the index values for HRQoL required conversion to 3L 
values as reliable 5L index values are not yet available for 
all standard populations. Evidence from a previous RRID 
analysis on prior renal function change provided depth 
to our analyses for this cross- sectional study. However, 
there were also several important limitations—this was a 
Table 2 Comparison of the EQ- 5D- 5L quality- of- life 
domains between the Health Survey for England (HSE) 2012 
and the Renal Risk in Derby (RRID) cohort
HSE 2012 
cohort* (n=258)
RRID CKD 
cohort (n=1008)
n % n %
Mobility
  1 (no problems in 
walking about)
128 49.6 426 42.3
  2–5 (some 
problems)
130 50.4 582 57.7
Self- care
  1 (no problems 
washing or 
dressing)
209 81.0 842 83.5
  2–5 (some 
problems)
49 19.0 166 16.5
Usual activities
  1 (no problems 
doing usual 
activities)
142 55.0 542 53.8
  2–5 (some 
problems)
116 45.0 466 46.2
Pain/discomfort
  1 (no pain or 
discomfort)
103 39.9 296 29.4
  2–5 (some pain or 
discomfort)
155 60.1 712 70.6
Anxiety/depression
  1 (not anxious or 
depressed)
188 72.9 689 68.4
  2–5 (some anxiety 
or depression)
70 27.1 319 31.6
*All participants were aged 65 years or above.
CKD, chronic kidney disease.
Figure 2 Relationship between quality of life and functional 
status. (A) Functional status (by Karnofsky score) and quality 
of life (by EQ- 5D- 3L Index score). (B) Functional status (by 
Karnofsky score) and quality of life (by EQ- 5D self- reported 
visual analogue scale (VAS)).
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cross- sectional study of survivors and we were therefore 
not able to draw causative links. HRQoL and FS measures 
were taken at 5- year follow- up but not at baseline and 
we were therefore unable to identify change over time. 
The RRID cohort predominantly comprises people of 
white ethnicity, limiting generalisability of our findings. 
Comparison with HSE data was undertaken only via 
univariable analyses, such that potential confounding 
factors may have influenced the differences observed 
between the two groups. We also did not have sufficient 
numbers to allow for reliable exploration of associations 
between specific comorbidities and HRQoL or FS. We 
also recognise the need for caution in the interpretation 
of the associations between functional impairment and 
problems in individual domains due to small numbers 
in some individual categories (leading to wide CIs). A 
further limitation is that one inclusion criterion was the 
ability to attend study visits, which would have resulted in 
some selection bias by excluding the very frail.
People with CKD are likely to have multiple comorbid-
ities due both to the nature of the disease process and 
the relationship between CKD and older age. We have 
identified that comorbidity count was an independent 
determinant of both HRQoL and FS, highlighting the 
importance of a holistic approach that includes atten-
tion to comorbidities in the management of people with 
Table 3 Logistic regression models examining associations between lower quality of life (EQ- 5D- 5L mobility domain 
categorised as ‘no problems’ vs ‘any problems’) and patient characteristics
Univariable Multivariable*
OR (95% CI) P value OR (95% CI) P value
Age (years) 1.05 (1.03 to 1.07) <0.001 1.03 (1.02 to 1.05) 0.001
Female sex (vs male) 1.16 (0.89 to 1.49) 0.27 – –
Index of Multiple Deprivation (IMD quintile relative to England) (vs quintile 5: least deprived) (n=1006)
  Quintile 1 (most deprived) 1.61 (0.96 to 2.69) 0.04† 0.95 (0.52 to 1.74) 0.436†
  Quintile 2 1.69 (1.17 to 2.43) 1.38 (0.90 to 2.10)
  Quintile 3 1.10 (0.75 to 1.62) 0.94 (0.60 to 1.48)
  Quintile 4 1.25 (0.88 to 1.78) 1.17 (0.78 to 1.76)
Number of comorbidities (vs no comorbidities)
  One 1.25 (0.70 to 2.24) <0.001† 1.01 (0.53 to 1.93) 0.002†
  Two 2.43 (1.35 to 4.38) 1.40 (0.72 to 2.71)
  Three or more 4.50 (2.49 to 8.12) 2.10 (1.08 to 4.10)
Functional status (KPS score) (vs KPS >70)
  Functional impairment (KPS ≤70) 26.03 (13.60 to 49.81) <0.001 16.87 (8.70 to 32.79) <0.001
eGFR (mL/min/1.73 m2) (N=1007)
0.98 (0.98 to 0.99) <0.001 0.99 (0.99 to 1.01) 0.983
uACR (KDIGO categories) (vs category A1,<3 mg/mmol) (n=1007)
  A2 (3–29 mg/mmol) 1.39 (1.02 to 1.91) 0.074† 1.01 (0.69 to 1.48) 0.937†
  A3 (≥30 mg/mmol) 1.42 (0.78 to 2.57) 0.88 (0.41 to 1.85)
Educational attainment (vs first or higher degree or NVQ 4–5) (n=1007)
  No formal qualifications 2.20 (1.59 to 3.05) <0.001† 1.38 (0.93 to 2.04) 0.238†
  GCSE, A level or NVQ 1–3 1.23 (0.86 to 1.76) 1.13 (0.75 to 1.70)
BMI (vs <25 kg/m2)
  Overweight (BMI 25–29.99 kg/m2) 1.51 (1.07 to 2.13) <0.001† 1.37 (0.93 to 2.01) <0.001†
  Obese (BMI ≥30 kg/m2) 3.24 (2.26 to 4.63) 2.44 (1.61 to 3.69)
Smoking status (vs never smoked)
  Current smoker 1.50 (0.79 to 2.87) 0.413† – –
  Ex- smoker 1.10 (0.85 to 1.42) –
n=1008 in univariable models unless otherwise stated; n=1005 for final multivariable logistic regression models.
*Adjusted for age, deprivation level, number of comorbidities, functional status, estimated glomerular filtration rate (eGFR) at 5- year follow- up, 
urinary albumin- to- creatinine ratio (uACR) at 5- year follow- up, educational attainment and body mass index (BMI).
†P value for trend.
GCSE, General Certificate of Secondary Education; KDIGO, Kidney Disease Improving Global Outcomes; KPS, Karnofsky Performance 
Status; A level, advanced level; NVQ, National Vocational Qualifications.;
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mild- to- moderate CKD. As reported previously, 40% of 
people in this cohort with stage 3 disease had at least 
two comorbidities.6 There are clearly shared risk factors 
for several of the included comorbidities. It is therefore 
perhaps unsurprising that in a large cohort of over half 
a million Canadian patients with CKD, comorbidities 
such as hypertension and diabetes were common (46.6% 
and 17.8%, respectively). However, a substantial number 
of patients also had ‘discordant’ comorbidities such as 
chronic pulmonary disease (14.0%) and 10.6% of patients 
had chronic pain.5 Comorbidities were all associated with 
an increased risk of hospitalisation.5 It is striking that the 
majority of people in our cohort reported problems with 
mobility and chronic pain/discomfort, and that both 
were more prevalent than in a nationally representative 
sample of the English general population of similar age. 
About 30% of our cohort were taking analgesic medica-
tion, but about 71% reported pain or discomfort in the 
EQ- 5D- 5L. This likely reflects the association of CKD with 
comorbidities, since mild- to- moderate reductions in GFR 
are unlikely to cause poor mobility or pain. Nevertheless, 
this observation further highlights the need to pay atten-
tion to mobility issues and pain management in order to 
improve quality of life in people with stage 3 CKD.
The prevalence of diabetes in this population of people 
with CKD stage 3 was 14.2%. This is lower than the prev-
alence of 20.1% noted in analyses of CKD prevalence 
in the HSE.2 It is possible that this relates to this study 
population comprising survivors at 5 years in a cohort 
study and those with diabetes may have been more likely 
to die prior to these analyses than those without. The 
study population was also predominantly white and those 
ethnic groups with greater diabetes prevalence were 
therefore under- represented.
Mental health problems are common with 26% of 
adults in England reporting a diagnosis at some point in 
time.24 In our study, about 6% of people were classified 
as having a depressive condition, defined pragmatically 
based on current antidepressant use or patient self- report, 
although about 32% reported some anxiety or depression 
in the EQ- 5D- 5L, so this was probably an underestimate. 
In a large meta- analysis, approximately 25% of adults with 
CKD stage 1–5 had symptoms suggestive of depression.25 
This appears to persist even in milder forms of the disease 
and a large study from 2012 showed the prevalence of 
depression in people with CKD whose eGFR was ≥60 mL/
min/1.73 m2 was 23.6%.26 These data imply that careful 
attention to mental health problems, including screening 
for depression, may also be key interventions to improve 
HRQoL in people with mild- to- moderate CKD.
Being able to carry out activities of daily living (ADLs) 
is an important part of living independently. There 
is a recognised association between having difficulty 
with ADLs and a lower HRQoL in older adults, though 
comparison of HRQoL (as assessed by EQ- 5D- 5L) with 
FS (as assessed by the KPS) is understudied.27 The 
strong association observed in this study between func-
tional impairment and lower HRQoL including mobility, 
self- care and usual activities, even after adjustment for 
potential confounding factors, suggests that clinicians 
identifying functional impairment should consider 
their patient’s HRQoL. Previous research has identified 
higher prevalence of problems with ADLs among people 
with CKD (defined as eGFR <60 mL/min/1.73 m2) than 
people without, variously reported as between 26% and 
55% depending on the nature of the population studied 
and the measure of ADL used.28–30 Two large longitudinal 
studies have shown, in keeping with our findings, a signif-
icant reduction in instrumental ADLs and basic ADLs 
when renal function deteriorates over time.28 29 It should 
also be noted that the KPS is a clinician- assessed tool 
comprising an element of subjectivity and therefore may 
be less accurate than an in- depth questionnaire looking 
at both instrumental ADLs and generic ADLs.
In 2016, NICE published their first guideline for the 
management of individuals with multiple coexisting 
chronic diseases.31 These guidelines ask clinicians to 
consider the overall burdens of disease and treatment, 
Table 4 Summary matrix of the independent associations with ‘some problems’ in each domain of the EQ- 5D- 5L (from 
multivariable logistic regression analyses)
Mobility Self- care Usual activities Pain/discomfort Anxiety/depression
Increasing age Ο     
Female sex     Ο
Greater area deprivation level      
Higher number of comorbidities Ο Ο Ο Ο  
Functional impairment Ο Ο Ο Ο Ο
Lower eGFR      
Higher level of albuminuria      
Lower educational attainment     Ο
Higher BMI Ο Ο Ο Ο  
Smoking  Ο    
BMI, body mass index; eGFR, estimated glomerular filtration rate.
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and to discuss these with patients and develop individ-
ualised management plans. Among other things, they 
suggest that clinicians assess for frailty (using measures 
such as gait speed or self- reported health status) and 
remain particularly vigilant for issues with mental health 
or chronic pain.31 Our data provide evidence that a similar 
approach is warranted in people with mild- to- moderate 
CKD. When managing these patients, clinicians should 
consider comorbidities and discuss how treatments will 
fit in with those for other comorbidities, particularly 
mental health and chronic pain- related conditions and 
those affecting mobility. Obesity, as a potentially modi-
fiable factor with an independent association with both 
functional impairment and HRQoL in our study, is also 
an important consideration. This could include devising 
management plans jointly with other healthcare profes-
sionals, streamlining health services to cater for people 
with multiple conditions, and signposting to appropriate 
services. Both general practitioners and nephrologists 
should be well placed to manage patients holistically, but 
patients would benefit from mental health, comorbidity 
and pain issues being considered in clinical guidelines 
and outcome measures. It is also important to consider 
the capacity of people to self- manage, and the extent 
of patient activation, if mental health issues or multiple 
comorbidities are present.
CONCLUSION
We have observed that people with mild- to- moderate 
CKD commonly have multiple comorbidities and many 
report some HRQoL problems and functional impair-
ment. Taken together with previous observations that the 
risk of CKD progression is low in this context, these data 
suggest that mild- to- moderate CKD in older people could 
be more important as a marker of increased comorbidity 
Table 5 Logistic regression models of the associations between clinician- assessed functional impairment (Karnofsky 
Performance Status score ≤70) and patient characteristics
Univariable Multivariable*
OR (95% CI) P value OR (95% CI) P value
Age (years) 1.07 (1.05 to 1.09) <0.001 1.07 (1.04 to 1.09) <0.001
Sex (vs male) 1.15 (0.85 to 1.56) 0.371 1.32 (0.91 to 1.91) 0.148
Index of Multiple Deprivation (IMD quintile relative to England) (vs quintile 5: least deprived) (n=1006)
  Quintile 1 (most deprived) 2.77 (1.55 to 4.95) 0.003† 2.03 (1.06 to 3.87) 0.045†
  Quintile 2 2.19 (1.39 to 3.44) 2.05 (1.24 to 3.40)
  Quintile 3 1.83 (1.12 to 2.98) 2.02 (1.17 to 3.47)
  Quintile 4 1.64 (1.03 to 2.59) 1.65 (1.00 to 2.75)
Number of comorbidities (vs no comorbidities)
  One 1.18 (0.44 to 3.18) <0.001† 0.62 (0.22 to 1.77) <0.001†
  Two 3.10 (1.19 to 8.08) 1.22 (0.44 to 3.38)
  Three or more 5.97 (2.32 to 15.35) 2.18 (0.80 to 5.96)
eGFR (mL/min/1.73 m2) (n=1007)
0.97 (0.96 to 0.98) <0.001 0.99 (0.98 to 1.00) 0.186
uACR (KDIGO categories) (vs category A1, <3 mg/mmol) (n=1007)
  A2 (3–29 mg/mmol) 1.92 (1.37 to 2.70) 0.002† 1.92 (1.29 to 2.87) 0.005†
  A3 (≥30 mg/mmol) 1.96 (1.05 to 3.66) 1.74 (0.82 to 3.68)
Educational attainment (vs first or higher degree or NVQ 4–5) (n=1007)
  No formal qualifications 2.77 (1.81 to 4.26) <0.001† 2.08 (1.26 to 3.41) <0.001†
  GCSE, A level or NVQ 1–3 1.07 (0.65 to 1.77) 0.99 (0.56 to 1.75)
BMI (vs <25 kg/m2)
  Overweight (BMI 25–29.99 kg/m2) 1.54 (0.94 to 2.53) <0.001† 1.59 (0.93 to 2.73) <0.001†
  Obese (BMI ≥30 kg/m2) 3.76 (2.34 to 6.04) 4.23 (2.48 to 7.20)
Smoking status (vs never smoked)
  Current smoker 1.37 (0.70 to 2.71) 0.563† – –
  Ex- smoker 0.95 (0.70 to 1.28) –
N=1008 in univariable models unless otherwise stated; N=1004 for final multivariable logistic regression model.
*Adjusted for age, sex, deprivation level, number of comorbidities, estimated glomerular filtration rate (eGFR) at 5- year follow- up, albumin–creatinine 
ratio, educational attainment and body mass index (BMI).
†P value for trend.
GCSE, General Certificate of Secondary Education; KDIGO, Kidney Disease Improving Global Outcomes; A level, advanced level; NVQ, National 
Vocational Qualifications; uACR, urine albumin–creatinine ratio.
 o
n
 Septem
ber 4, 2020 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2020-040286 on 6 August 2020. Downloaded from 
10 Fraser SDS, et al. BMJ Open 2020;10:e040286. doi:10.1136/bmjopen-2020-040286
Open access 
than as a risk factor for ESKD. Clinicians should therefore 
carefully consider comorbidities and discuss how treat-
ments will fit in with those for other comorbidities, partic-
ularly mental health, chronic pain- related conditions and 
those affecting FS.
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